DE602004021095D1 - Verfahren zum screening der leichten kette eines antikörpers - Google Patents

Verfahren zum screening der leichten kette eines antikörpers

Info

Publication number
DE602004021095D1
DE602004021095D1 DE602004021095T DE602004021095T DE602004021095D1 DE 602004021095 D1 DE602004021095 D1 DE 602004021095D1 DE 602004021095 T DE602004021095 T DE 602004021095T DE 602004021095 T DE602004021095 T DE 602004021095T DE 602004021095 D1 DE602004021095 D1 DE 602004021095D1
Authority
DE
Germany
Prior art keywords
antibody
library
desired antigen
screening
heavy chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE602004021095T
Other languages
English (en)
Inventor
Tetsuo Kojima
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chugai Pharmaceutical Co Ltd
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of DE602004021095D1 publication Critical patent/DE602004021095D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
DE602004021095T 2003-01-21 2004-01-21 Verfahren zum screening der leichten kette eines antikörpers Expired - Lifetime DE602004021095D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2003012648 2003-01-21
PCT/JP2004/000496 WO2004065611A1 (ja) 2003-01-21 2004-01-21 抗体の軽鎖スクリーニング方法

Publications (1)

Publication Number Publication Date
DE602004021095D1 true DE602004021095D1 (de) 2009-06-25

Family

ID=32767339

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004021095T Expired - Lifetime DE602004021095D1 (de) 2003-01-21 2004-01-21 Verfahren zum screening der leichten kette eines antikörpers

Country Status (6)

Country Link
US (1) US8337841B2 (de)
EP (1) EP1605058B1 (de)
JP (1) JP4477579B2 (de)
AT (1) ATE431423T1 (de)
DE (1) DE602004021095D1 (de)
WO (1) WO2004065611A1 (de)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003087163A1 (fr) * 2002-04-15 2003-10-23 Chugai Seiyaku Kabushiki Kaisha Procede d'elaboration d'une banque scdb
JP4794301B2 (ja) * 2003-06-11 2011-10-19 中外製薬株式会社 抗体の製造方法
WO2005035753A1 (ja) 2003-10-10 2005-04-21 Chugai Seiyaku Kabushiki Kaisha 機能蛋白質を代替する二重特異性抗体
EP2311945A1 (de) * 2003-10-14 2011-04-20 Chugai Seiyaku Kabushiki Kaisha Bispezifische Antikörper, die funktionale Proteine ersetzen
WO2005056602A1 (ja) * 2003-12-12 2005-06-23 Chugai Seiyaku Kabushiki Kaisha アゴニスト活性を有する改変抗体のスクリーニング方法
EP1710255A4 (de) * 2003-12-12 2008-09-24 Chugai Pharmaceutical Co Ltd Modifizierte antikörper, die rezeptortrimere oder höhere multimere erkennen
TW200530269A (en) 2003-12-12 2005-09-16 Chugai Pharmaceutical Co Ltd Anti-Mpl antibodies
TW200722518A (en) * 2005-03-31 2007-06-16 Chugai Pharmaceutical Co Ltd Sc(fv)2 structural isomers
AU2006232287B2 (en) 2005-03-31 2011-10-06 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
WO2006109592A1 (ja) * 2005-04-08 2006-10-19 Chugai Seiyaku Kabushiki Kaisha 血液凝固第viii因子の機能代替抗体
EP3348639A3 (de) * 2005-06-10 2018-10-31 Chugai Seiyaku Kabushiki Kaisha Stellengerichtete sc(fv)2-mutante
US9241994B2 (en) 2005-06-10 2016-01-26 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical compositions containing sc(Fv)2
CA2610987C (en) * 2005-06-10 2013-09-10 Chugai Seiyaku Kabushiki Kaisha Stabilizer for protein preparation comprising meglumine and use thereof
US20100168393A1 (en) * 2005-10-11 2010-07-01 Big Glucose Ltd. Antibody Polypeptide Libray Screening and Selected Antibody Polypeptides
JP5144499B2 (ja) 2006-03-31 2013-02-13 中外製薬株式会社 二重特異性抗体を精製するための抗体改変方法
EP4342995A2 (de) 2006-03-31 2024-03-27 Chugai Seiyaku Kabushiki Kaisha Verfahren zur kontrolle der blut-pharmazeutizität von antikörpern
EP3127921A1 (de) 2007-09-26 2017-02-08 Chugai Seiyaku Kabushiki Kaisha Verfahren zur modifizierung eines isoelektrischen punkts eines antikörpers über aminosäuresubstition in cdr
DK2329020T3 (da) 2008-08-28 2013-06-10 Novartis Ag Celleoverfladepræsentation af polypeptidisoformer ved hjælp af stopcodon-overspringelse
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
ES2603559T5 (es) 2010-02-08 2021-02-22 Regeneron Pharma Cadena ligera común de ratón
EP3741883B1 (de) 2010-07-16 2022-12-14 Adimab, LLC Antikörperbibliotheken
MX355060B (es) 2010-11-17 2018-04-03 Chugai Pharmaceutical Co Ltd Molecula multiespecifica de union a antigeno que tiene funcion alternativa a la funcion del factor viii de coagulacion sanguinea.
US11066483B2 (en) 2010-11-30 2021-07-20 Chugai Seiyaku Kabushiki Kaisha Cytotoxicity-inducing therapeutic agent
SG10201606158TA (en) 2011-08-05 2016-09-29 Regeneron Pharma Humanized universal light chain mice
EP2825036B1 (de) 2012-03-16 2018-05-02 Regeneron Pharmaceuticals, Inc. Durch histidin manipulierte leichtkettige antikörper und genetisch modifizierte nager zur erzeugung davon
US20140013456A1 (en) 2012-03-16 2014-01-09 Regeneron Pharmaceuticals, Inc. Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
US9301510B2 (en) 2012-03-16 2016-04-05 Regeneron Pharmaceuticals, Inc. Mice that produce antigen-binding proteins with pH-dependent binding characteristics
KR102459666B1 (ko) 2012-03-16 2022-10-27 리제너론 파마슈티칼스 인코포레이티드 pH-민감성 면역글로불린 서열을 발현하는 비-사람 동물
US9969813B2 (en) * 2012-05-10 2018-05-15 Bioatla, Llc Multi-specific monoclonal antibodies
JP6534615B2 (ja) 2013-09-27 2019-06-26 中外製薬株式会社 ポリペプチド異種多量体の製造方法
EP3037525B1 (de) 2013-09-30 2021-06-02 Chugai Seiyaku Kabushiki Kaisha Verfahren zur herstellung eines antigenbindenden moleküls unter verwendung von modifizierten helferphagen
KR102601491B1 (ko) 2014-03-21 2023-11-13 리제너론 파마슈티칼스 인코포레이티드 단일 도메인 결합 단백질을 생산하는 비-인간 동물
WO2015153765A1 (en) * 2014-04-01 2015-10-08 Adimab, Llc Multispecific antibody analogs comprising a common light chain, and methods of their preparation and use
JP6974943B2 (ja) 2014-05-13 2021-12-01 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア ２種の抗体構築物を発現するａａｖを含む組成物およびこの使用
MA40764A (fr) * 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
TWI700300B (zh) * 2014-09-26 2020-08-01 日商中外製藥股份有限公司 中和具有第ｖｉｉｉ凝血因子（ｆｖｉｉｉ）機能替代活性的物質之抗體
TWI701435B (zh) 2014-09-26 2020-08-11 日商中外製藥股份有限公司 測定ｆｖｉｉｉ的反應性之方法
CN107438622A (zh) 2015-03-19 2017-12-05 瑞泽恩制药公司 选择结合抗原的轻链可变区的非人动物
US11142587B2 (en) 2015-04-01 2021-10-12 Chugai Seiyaku Kabushiki Kaisha Method for producing polypeptide hetero-oligomer
EP3378488A4 (de) 2015-11-18 2019-10-30 Chugai Seiyaku Kabushiki Kaisha Verfahren zur verbesserung der humoralen immunreaktion
WO2017086367A1 (ja) 2015-11-18 2017-05-26 中外製薬株式会社 免疫抑制機能を有する細胞に対するｔ細胞リダイレクト抗原結合分子を用いた併用療法
SG11201803989WA (en) 2015-12-28 2018-06-28 Chugai Pharmaceutical Co Ltd Method for promoting efficiency of purification of fc region-containing polypeptide
US11072666B2 (en) 2016-03-14 2021-07-27 Chugai Seiyaku Kabushiki Kaisha Cell injury inducing therapeutic drug for use in cancer therapy
MA46200A (fr) 2016-09-06 2019-07-17 Chugai Pharmaceutical Co Ltd Procédés d'utilisation d'un anticorps bispécifique qui reconnaît le facteur de coagulation ix et/ou le facteur de coagulation ix activé et le facteur de coagulation x et/ou le facteur de coagulation x activé
US20210206882A1 (en) 2017-08-01 2021-07-08 Ab Studio Inc. Bispecific antibodies and uses thereof
PE20210005A1 (es) 2017-09-29 2021-01-05 Chugai Pharmaceutical Co Ltd Molecula de union al antigeno multiespecifica que tiene actividad de sustitucion de la funcion de cofactor del factor viii de coagulacion de sangre (fviii) y formulacion farmaceutica que contiene tal molecula como ingrediente activo
JP7314146B2 (ja) 2017-12-28 2023-07-25 中外製薬株式会社 細胞傷害誘導治療剤
EP3561703B1 (de) * 2018-04-25 2021-01-20 Bayer AG Identifizieren der paarung von variablen domänen aus leichten und schweren ketten von antikörpern
EP3812399A4 (de) 2018-06-20 2022-03-23 Chugai Seiyaku Kabushiki Kaisha Verfahren zur aktivierung der immunantwort einer zielzelle und zusammensetzung dafür
WO2020205504A1 (en) * 2019-03-29 2020-10-08 Compass Therapeutics Llc Common light chains and methods of use
EP4023230A4 (de) 2019-06-05 2023-11-15 Chugai Seiyaku Kabushiki Kaisha Antikörper-spaltungsstellenbindendes molekül
JP2023106635A (ja) 2020-04-17 2023-08-02 中外製薬株式会社 二重特異性抗原結合分子ならびに、それに関連する組成物、組成物の製造のための使用、キット、および方法
TW202220677A (zh) 2020-07-31 2022-06-01 日商中外製藥股份有限公司 含有表現嵌合受體之細胞的醫藥組成物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
EP0871673B1 (de) 1995-05-03 2006-04-05 Bioenhancementsments Ltd. Bispezifische antikörper in denen die bindungsfähigkeit durch eine mittels licht spaltbare gruppe reversibel inhibiert wird
CA2288600C (en) 1997-05-02 2010-06-01 Genentech, Inc. A method for making multispecific antibodies having heteromultimeric and common components
DE19819846B4 (de) 1998-05-05 2016-11-24 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Multivalente Antikörper-Konstrukte
US6897044B1 (en) 1999-01-28 2005-05-24 Biogen Idec, Inc. Production of tetravalent antibodies
WO2001044282A2 (en) 1999-12-14 2001-06-21 The Burnham Institute Bcl-g polypeptides, encoding nucleic acids and methods of use
JP2003527849A (ja) 2000-03-22 2003-09-24 キュラゲン コーポレイション 新規ペプチド及びこれをコードする核酸
CA2429544C (en) * 2000-11-17 2010-10-19 University Of Rochester In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells
AU2002319402B2 (en) * 2001-06-28 2008-09-11 Domantis Limited Dual-specific ligand and its use
WO2003087163A1 (fr) 2002-04-15 2003-10-23 Chugai Seiyaku Kabushiki Kaisha Procede d'elaboration d'une banque scdb
CN100480260C (zh) * 2002-07-18 2009-04-22 克鲁塞尔荷兰公司 抗体混合物的重组生产
JP4794301B2 (ja) 2003-06-11 2011-10-19 中外製薬株式会社 抗体の製造方法

Also Published As

Publication number Publication date
US8337841B2 (en) 2012-12-25
JP4477579B2 (ja) 2010-06-09
ATE431423T1 (de) 2009-05-15
JPWO2004065611A1 (ja) 2006-05-18
EP1605058B1 (de) 2009-05-13
US20060159673A1 (en) 2006-07-20
EP1605058A1 (de) 2005-12-14
EP1605058A4 (de) 2006-04-19
WO2004065611A1 (ja) 2004-08-05

Similar Documents

Publication Publication Date Title
ATE431423T1 (de) Verfahren zum screening der leichten kette eines antikörpers
EP3202786A3 (de) Sequenzbasierte herstellung und optimierung von einzelkettenantikörpern
WO2009000098A3 (en) Sequence based engineering and optimization of single chain antibodies
NO20052181D0 (no) Fremgangsmate og apparat for a posisjonere et sentrum for en seismisk kilde
AR095980A1 (es) Anticuerpos biespecíficos específicos para fap (proteína de activación fibroblástica) y dr5 (receptor de muerte 5), anticuerpos específicos para dr5 y métodos de utilización
NO20054351L (no) Monoklonalt antistoff og hybridom som produserer dette
NO20061786L (no) Fremgangsmate for 3D forutsigelse av fri-overflate-multipler
ATE408684T1 (de) Verfahren zur verbesserung von t-zellrezeptoren
DK1716181T3 (da) CDR-reparerede antistoffer
WO2005072112A3 (en) Methods for producing and identifying multispecific antibodies
CY1111966T1 (el) Αντισωματα που δεσμευονται με κυτταροσυνδετο ca 125/0722ρ και μεθοδοι χρησεις αυτων
DK1054018T3 (da) Fab-fragmentbiblioteker og fremgangsmåde til anvendelse deraf
ATE276359T1 (de) Verfahren zur herstellung von antikörperfragmenten
ATE445645T1 (de) Verfahren zur selektion von anti-angiogenese antikörperfragmenten
DE60130211D1 (de) Matrix-screening-verfahren
WO2003087758A3 (en) Peptides for detection of antibody to a. phagocytophila
WO2010036851A3 (en) Single chain antibody library design
WO2008081331A3 (en) Enhancing the level of antibody expression by framework re-engineering
IL164625A (en) Method for producing a plurality of monoclonal antibodies and method for identifying a plurality of monoclonal antibodies
WO2005049652A3 (en) Methods of generating antibody diversity in vitro
DE50313529D1 (de) Verfahren und computer zur planung von versuchen
ATE432469T1 (de) Auf immunreaktion gegen boris basierendes verfahren für den nachweis von krebs
DE60120942D1 (de) Verbessertes verfahren für reverses n-hybrid-screening
Picconi et al. Intermediate photofragment distributions as probes of non-adiabatic dynamics at conical intersections: application to the Hartley band of ozone
DE602005021875D1 (de) Nachweisverfahren für einen liganden der selektiv eine funktionelle kaskade modulieren kann und ein target impliziert sowie dessen verwendung für hochdurchsatz-screening von molekülen die von interesse sind

Legal Events

Date Code Title Description
8364 No opposition during term of opposition